Crizotinib-induced cardiotoxicity: the importance of a proactive monitoring and management

Future Oncol. 2015;11(14):2043-8. doi: 10.2217/fon.15.47.

Abstract

Crizotinib is a multitarget tyrosine kinase inhibitor and it represents the standard of care in patients with anaplastic lymphoma kinase translocated non-small-cell lung cancer. Crizotinib is generally well tolerated and the most frequent adverse events include gastrointestinal effects, visual disorders, edema, fatigue and liver enzyme abnormalities. However, due to the increasing clinical experience with crizotinib, other toxicities are emerging, such as Q-wave T-wave interval prolongation and bradycardia. In the current review we will focus on the management of crizotinib-related cardiotoxicity.

Keywords: ALK-positive non-small-cell lung cancer; cardiotoxicity; crizotinib; drug interactions.

Publication types

  • Review

MeSH terms

  • Anaplastic Lymphoma Kinase
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use
  • Bradycardia / chemically induced
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Cardiotoxicity / diagnosis
  • Cardiotoxicity / prevention & control
  • Cardiotoxicity / therapy*
  • Crizotinib
  • Drug Interactions
  • Heart Rate / drug effects
  • Humans
  • Lung Neoplasms / drug therapy
  • Protein Kinase Inhibitors / adverse effects*
  • Pyrazoles / adverse effects*
  • Pyridines / adverse effects*
  • Receptor Protein-Tyrosine Kinases / metabolism

Substances

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyridines
  • Crizotinib
  • ALK protein, human
  • Anaplastic Lymphoma Kinase
  • Receptor Protein-Tyrosine Kinases